FZR1 Loss Exposes an ATR Inhibitor Vulnerability in ALL
A peer-reviewed online-first study identifies FZR1 deficiency as a candidate biomarker for sensitivity to ATR inhibition in relapsed or refractory acute lymphoblastic leukemia. The result connects a defined cell-cycle defect to a pharmacologic synthetic-lethal…
